Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing
- Lexaria, a global innovator in drug delivery platforms, recently completed dosing of its human pilot study #2, GLP-1-H24-2
- The study is to explore the tolerability, side effects, and blood levels of semaglutide, a glucagon-like peptide-1 (“GLP-1”) drug
- For Lexaria, the results from this study look to validate earlier studies that have demonstrated improvements in the delivery of semaglutide into the bloodstream
- Results from the GLP-1-H24-2 study are set to be announced in late August or early September
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the dosing completion of its human pilot study #2, GLP-1-H24-2. Lexaria’s patented DehydraTECH(TM) “drug delivery platform technology” increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of APIs. The potential of effective oral delivery of GLP -1 drugs, a class of drugs used to address diabetes and weight loss, represents a vast global market potential for DehydraTECH.
Blood samples collected throughout the study have been transported to the bioanalytical lab for analysis, and the organization looks to complete the analysis and announce the results in late August or early September.
“Lexaria is delighted that our contracted clinical research organization was able to complete the active phase of the study on schedule,” noted Chris Bunka, Lexaria’s CEO. “The results of this Study are expected to validate our earlier work with semaglutide, and also to discover whether it is possible to achieve any absorption of this market-leading GLP-1 drug through the tissues of the mouth,” he added (https://nnw.fm/63SvO ).
This study explored tolerability, side effects, and blood levels of semaglutide, a glucagon-like peptide-1 (“GLP-1”) drug. It also sought to measure blood glucose and insulin levels, highlighting the drug’s potential in treating diabetes and weight loss. The study comprised three primary arms, each of which compared three 7mg semaglutide dose formulations. The first arm was a positive control of Rybelsus(R), the only GLP-1 drug approved by the FDA for oral dosing to treat diabetes and weight loss. The second arm saw the use of Lexaria’s patented DehydraTECH technology in processing semaglutide in swallowed tablets. The last arm was an in-mouth dissolvable DehydraTECH-semaglutide oral tablet, a first in the industry.
This final study arm will be the first to investigate whether DehydraTECH-enhanced semaglutide can be absorbed systemically at any level through the sublingual/buccal tissues of the mouth and throat with fewer side effects than swallowed administration. It takes into account the stomach’s acidic environment, which seriously degrades GLP-1 drugs that are swallowed, resulting in meager blood absorption rates of less than 1% when an absorption technology is not used.
Previous Lexaria studies have demonstrated improvements in the delivery of semaglutide into the bloodstream and in controlling blood sugar. They also demonstrated that DehydraTECH GLP-1 processed semaglutide is generally better tolerated than the Rybelsus(R) tablets themselves, with the latter often resulting in instances of moderate diarrhea and nausea. GLP-1-H24-2 looks to validate these results and more, further pointing to the superiority of its DehydraTECH technology and highlighting its potential in treating diabetes and weight loss.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- Lexaria, a global innovator in drug delivery platforms, recently completed dosing of its human pilot study #2, GLP-1-H24-2
- The study is to explore the tolerability, side effects, and blood levels of semaglutide, a glucagon-like peptide-1 (“GLP-1”) drug
- For Lexaria, the results from this study look to validate earlier studies that have demonstrated improvements in the delivery of semaglutide into the bloodstream
- Results from the GLP-1-H24-2 study are set to be announced in late August or early September
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the dosing completion of its human pilot study #2, GLP-1-H24-2. Lexaria’s patented DehydraTECH(TM) “drug delivery platform technology” increases bioavailability, improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery, helping with speed of onset, and brain absorption of APIs. The potential of effective oral delivery of GLP -1 drugs, a class of drugs used to address diabetes and weight loss, represents a vast global market potential for DehydraTECH.
Blood samples collected throughout the study have been transported to the bioanalytical lab for analysis, and the organization looks to complete the analysis and announce the results in late August or early September.
“Lexaria is delighted that our contracted clinical research organization was able to complete the active phase of the study on schedule,” noted Chris Bunka, Lexaria’s CEO. “The results of this Study are expected to validate our earlier work with semaglutide, and also to discover whether it is possible to achieve any absorption of this market-leading GLP-1 drug through the tissues of the mouth,” he added (https://nnw.fm/63SvO ).
This study explored tolerability, side effects, and blood levels of semaglutide, a glucagon-like peptide-1 (“GLP-1”) drug. It also sought to measure blood glucose and insulin levels, highlighting the drug’s potential in treating diabetes and weight loss. The study comprised three primary arms, each of which compared three 7mg semaglutide dose formulations. The first arm was a positive control of Rybelsus(R), the only GLP-1 drug approved by the FDA for oral dosing to treat diabetes and weight loss. The second arm saw the use of Lexaria’s patented DehydraTECH technology in processing semaglutide in swallowed tablets. The last arm was an in-mouth dissolvable DehydraTECH-semaglutide oral tablet, a first in the industry.
This final study arm will be the first to investigate whether DehydraTECH-enhanced semaglutide can be absorbed systemically at any level through the sublingual/buccal tissues of the mouth and throat with fewer side effects than swallowed administration. It takes into account the stomach’s acidic environment, which seriously degrades GLP-1 drugs that are swallowed, resulting in meager blood absorption rates of less than 1% when an absorption technology is not used.
Previous Lexaria studies have demonstrated improvements in the delivery of semaglutide into the bloodstream and in controlling blood sugar. They also demonstrated that DehydraTECH GLP-1 processed semaglutide is generally better tolerated than the Rybelsus(R) tablets themselves, with the latter often resulting in instances of moderate diarrhea and nausea. GLP-1-H24-2 looks to validate these results and more, further pointing to the superiority of its DehydraTECH technology and highlighting its potential in treating diabetes and weight loss.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://nnw.fm/LEXX
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
